We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
-0.05%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$17.5B
AUM Growth
-$4.53B
Cap. Flow
-$3.73B
Cap. Flow %
-21.26%
Top 10 Hldgs %
49.23%
Holding
203
New
48
Increased
29
Reduced
30
Closed
31

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$292M
2
KKR icon
KKR & Co
KKR
+$280M
3
ROIV icon
Roivant Sciences
ROIV
+$248M
4
MA icon
Mastercard
MA
+$138M
5
TMO icon
Thermo Fisher Scientific
TMO
+$133M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$650M
2
CYBR
CyberArk
CYBR
+$470M
3
CRM icon
Salesforce
CRM
+$334M
4
NDAQ icon
Nasdaq
NDAQ
+$290M
5
RNAM
Avidity Biosciences
RNAM
+$233M

Sector Composition

Rank Sector Weight
1 Healthcare 50.56%
2 Financials 12.21%
3 Technology 11.18%
4 Consumer Discretionary 5.09%
5 Industrials 3.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALVO icon
101
Alvotech
ALVO
$1.17B
$685K ﹤0.01%
199,675
– –
AXSM icon
102
Axsome Therapeutics
AXSM
$11.8B
$676K ﹤0.01%
4,000
– –
COGT icon
103
Cogent Biosciences
COGT
$6.68B
$654K ﹤0.01%
17,000
– –
ANNA
104
AleAnna Inc
ANNA
$141M
$650K ﹤0.01%
78,400
– –
ARQT icon
105
Arcutis Biotherapeutics
ARQT
$3.56B
$613K ﹤0.01%
26,000
– –
CELC icon
106
Celcuity
CELC
$4.31B
$457K ﹤0.01%
4,000
– –
LIVN icon
107
LivaNova
LIVN
$4.43B
$381K ﹤0.01%
6,000
– –
TERN
108
DELISTED
Terns Pharmaceuticals
TERN
$369K ﹤0.01%
7,000
-635,000
-99% -$26.1M
IONS icon
109
Ionis Pharmaceuticals
IONS
$8.99B
$360K ﹤0.01%
4,800
– –
TVTX icon
110
Travere Therapeutics
TVTX
$5.27B
$357K ﹤0.01%
12,000
– –
GMED icon
111
Globus Medical
GMED
$10.5B
$345K ﹤0.01%
4,000
– –
SRRK icon
112
Scholar Rock
SRRK
$6.33B
$344K ﹤0.01%
7,000
– –
ONC
113
BeOne Medicines Ltd
ONC
$32.4B
$327K ﹤0.01%
1,100
– –
WGS icon
114
GeneDx Holdings
WGS
$1.88B
$321K ﹤0.01%
5,000
-65,000
-93% -$5.93M
COR icon
115
Cencora
COR
$59.9B
$314K ﹤0.01%
1,000
– –
NUVL
116
DELISTED
Nuvalent
NUVL
$307K ﹤0.01%
3,000
– –
PGNY icon
117
Progyny
PGNY
$2.5B
$306K ﹤0.01%
18,000
– –
STOK icon
118
Stoke Therapeutics
STOK
$1.81B
$293K ﹤0.01%
9,000
– –
ERAS icon
119
Erasca
ERAS
$6.65B
$291K ﹤0.01%
+18,000
New +$213K
EHC icon
120
Encompass Health
EHC
$11.1B
$290K ﹤0.01%
3,000
-231,500
-99% -$23.7M
NKTR icon
121
Nektar Therapeutics
NKTR
$2.31B
$288K ﹤0.01%
+4,000
New +$228K
GKOS icon
122
Glaukos
GKOS
$9.21B
$280K ﹤0.01%
2,600
– –
MIRM icon
123
Mirum Pharmaceuticals
MIRM
$7.25B
$277K ﹤0.01%
3,000
– –
SBRA icon
124
Sabra Healthcare REIT
SBRA
$5.07B
$269K ﹤0.01%
14,000
– –
KRYS icon
125
Krystal Biotech
KRYS
$10.5B
$258K ﹤0.01%
1,000
-1,000
-50% -$266K
3 4
5
6 7

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Envestnet Portfolio Solutions
Envestnet Portfolio Solutions Chicago, Illinois $18.1B AUM 15% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return

Farallon Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Farallon Capital Management held 203 positions worth $17.5B, down 21% from $22.1B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Farallon Capital Management withdrew a net $3.73B in Q1 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was Exact Sciences, an estimated $650M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 43% a quarter earlier, followed by Financials and Technology.

Against the trend, Farallon Capital Management opened a new position in Dianthus Therapeutics worth $70.2M.

  • Farallon Capital Management's largest Q1 2026 buy was Dianthus Therapeutics: 836,000 shares worth $70.2M.
  • Farallon Capital Management added most to Broadcom in Q1 2026, an estimated $292M increase.
  • Farallon Capital Management's biggest Q1 2026 reduction was Wabtec, cutting an estimated $210M.
  • Farallon Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $650M.
  • Farallon Capital Management's ten largest holdings make up 49% of its $17.5B portfolio in Q1 2026.
  • Farallon Capital Management opened 48 new positions and closed 31 in Q1 2026.
  • Farallon Capital Management's portfolio value fell 21% quarter-over-quarter to $17.5B.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.